Molecular risk prediction in cutaneous melanoma: a meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients.

Like Comment
Multiple studies have reported on the accuracy of the prognostic 31-gene expression profile test (31-GEP) for cutaneous melanoma. Consistency of the test results across studies has not been systematically evaluated.To assess the robustness of the prognostic value of the 31-GEP.Raw data were obtained from studies identified from systematic review. A meta-analysis was performed to determine overall effect of the 31-GEP. Clinical outcome metrics for the 31-GEP were compared to AJCC staging.Three studies met inclusion criteria; data from a novel cohort of 211 patients were included (n=1,479). Five-year recurrence-free and distant metastasis-free survival (DMFS) rates were 91.4% and 94.1% for Class 1A patients and 43.6% and 55.5% for Class 2B patients (p<0.0001). Meta-analysis results show that Class 2 was significantly associated with recurrence (HR: 2.90; p<0.0001) and distant metastasis (HR: 2.75; p<0.0001). The 31-GEP identified AJCC stage I-III patient subsets with high likelihood for recurrence and distant metastasis. Sensitivity was 76% [95%CI 71-80%] and 76% [95%CI 70-82%] for each endpoint, respectively. When 31-GEP and sentinel lymph node biopsy results were considered together, sensitivity and negative predictive value for DMFS were both improved.The 31-GEP test consistently and accurately identifies melanoma patients at increased risk of metastasis, is independent of other clinicopathologic covariates, and augments current risk stratification by re-classifying patients previously designated as low risk, for heightened surveillance.

Click here to read the full article @ Journal of the American Academy of Dermatology
Go to the profile of ClinOwl


The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
2212 Contributions
0 Following

No comments yet.